Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...

We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

In the latest trading session, Eli Lilly (LLY) closed at $852.35, marking a -1.45% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.16%. On the other ...

Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 months, however, the stock's performance has been fairly lackluster ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...